SEPTIN9 and non-small cell lung carcinoma: The presence of methylated SEPT9 promoter region amplification was observed in 31 (44.3 % of the studied group) lung cancer patients (53 % of the NSCLC patients and 26 % of the SCLC patients), in a similar proportion in both genders.